Immutep
@Immutep
Followers
2K
Following
581
Statuses
923
A late-stage clinical biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease. (ASX: IMM, NASDAQ: IMMP)
Global
Joined February 2011
RT @sharecafetweets: Register now at for the next Sip & Learn webinar discussing biotech and resources, featuring I…
0
1
0
We’re pleased to provide our shareholders with a summary of a busy quarter in Q2 FY25, such as our transition to becoming a #PhaseIII biotech. Read the update: #biotechnology #LAG3 #immunotherapy
0
1
8
Patient enrolment has been completed for the PhII EFTISARC-NEO trial of efti in #softtissuesarcoma being conducted by the Maria Sklodowska-Curie National Research Institute of Oncology. Further data is expected in 2025. #immunooncology #LAG3 ASX:
1
0
4
Thank you to everyone who took the time to meet with @Immutep last week at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference. It was a busy week for our team! #JPM25 #JPM2025 #LifeSciences #Healthcare
1
0
8
Marc Voigt, CEO of @Immutep, was delighted to join @ausbiztv's Investor Event to discuss its recent advancements in cancer treatment and its promising outlook following encouraging trial results. Watch the short CEO interview: #biotechnology #LAG3
1
1
13
@Immutep announces the completion of patient enrolment for the INSIGHT-003 trial. This investigator-initiated study evaluates efti in combo with KEYTRUDA and doublet #chemotherapy as a first-line treatment for advanced/metastatic non-squamous #NSCLC.
1
1
11
ICYMI: Tune in to replay of fireside chat with Dr. Martin Forster of the @ucl Cancer Institute and @Immutep CEO Marc Voigt for an overview of recent data in 1L HNSCC patients with PD-L1 CPS <1 and insights into TACTI-004 Phase 3 in #lungcancer Replay:
0
1
6
@Immutep is pleased to announce favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating #IMP761. Read more: #biotechnology #AutoimmuneDisease #LAG3 #immunotherapy
1
6
17
@Immutep in collab with @RossjohnLab first to publish structure of LAG-3/HLA-II complex & resolve how human LAG-3 binds to its main ligand, providing better foundation for development of blocking #LAG3 therapeutics incl its own small molecule program.
0
5
16
@Immutep is proud to report new positive results from efti in combination with KEYTRUDA® at #ESMOIO2024 in first line #HNSCC patients with PD-L1 expression below 1 (CPS <1). Data shows strong overall & progression-free survival and durability. Read more:
2
3
13
@Immutep is thrilled to announce the initiation of the TACTI-004 Phase III for 1L metastatic #NSCLC that represents a major step towards a potential new standard of care. The first patient is expected to be enrolled in Q1 2025. Read: #biotechnology
0
1
15
CEO Marc Voigt joined the Frazis Capital Podcast to discuss #lungcancer challenges, the rise of #immunotherapy & Immutep’s innovative work. Hear about clinical trials, autoimmune research & the Company’s vision: #oncology #autoimmunediseases #LAG3
1
0
6
RT @TargetedOnc: In the phase 1 INSIGHT-003 trial, the combination of eftilagimod alpha, pembrolizumab, and chemotherapy showed promising r…
0
3
0
RT @Finnewsnetwork: Immutep (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results a…
0
4
0
@Immutep is pleased to share an Investor Update discussing the upcoming TACTI-004 trial & becoming a Phase 3 biotech. The potential for efti combined with KEYTRUDA & chemo is to set a new standard-of-care in #NSCLC Read more here: #LungCancerAwarenessMonth
1
2
12
RT @SmallCapsASX: Immutep’s (#ASX: $IMM) efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials http…
0
4
0